Bavarian Nordic A/S released a summary of its progress for the first half of 2016 on Wednesday.
“I am very pleased with the progress of the company this year,” Paul Chaplin, president and chief executive officer of Bavarian Nordic, said. “We have successfully built on our relationships with the U.S. and the Canadian governments, resulting in new supply orders for our Imvamune smallpox vaccine for delivery in 2016 and beyond. Additional discovery programs continue to be investigated with various governmental and health agencies as well.
“Internally, our pipeline has never been stronger, with phase 2 studies for both RSV and NSCLC starting this fall, and additional studies to follow shortly thereafter. Prostvac continues to proceed towards overall survival data in our phase 3 study, which we anticipate in 2017, and multiple studies continue to be initiated by our collaborators both as monotherapy and in combination.”
The summary also highlights the initiation of a phase 1 study of an MVA-BN based vaccine against yellow fever in July by the U.S. National Institute of Allergy and Infectious Diseases, the exercised option by the Public Health Agency of Canada for the supply of 171,000 doses of Imvamune to the national stockpile at a total value of $7.7 million, and the reception of a $12.3 million milestone payment from the Biomedical Advanced Research and Development Authority (BARDA) related to the development of Imvamune.